Jean Koff is an Oncology physician affiliated with Emory University. OpenAlex indexes 192 publications with 2,880 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
8 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65.3%Kinase inhibitor33.7%Imbruvica55%Brukinsa29%Calquence17%Part D<11 patientsBCL-2 Inhibitor31.6%Venclexta100%Part D<11 patientsAnti-infectives
14.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.8%Valacyclovir100%Part D≥13 patientsDermatology
7.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor7.7%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Hydrogel-based Organoids of African-American Lymphomas to Study B Cell Receptor Pathway Inhibitors
Georgia Institute of Technology
FY2026$546,993R01CA266052 - Hydrogel-based Organoids of African-American Lymphomas to Study B Cell Receptor Pathway Inhibitors
Georgia Institute of Technology
FY2025$547,532R01CA266052 - Hydrogel-based Organoids of African-American Lymphomas to Study B Cell Receptor Pathway Inhibitors
Georgia Institute of Technology
FY2024$520,646R01CA266052
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Guyton, MD
Emory University
Keith Delman, MD
Emory University
Paolo Raggi, MD
Emory University
Monica Farley, MD
Emory University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”